Verition Fund Management
ECYT

Verition Fund Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Verition Fund Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-17,869
Closed -$162K – 1462
2018
Q1 		$162K Buy
+17,869
New +$98.6K 0.01% 1030
2014
Q4 		– Sell
-12,891
Closed -$78K – 754
2014
Q3 		$78K Buy
+12,891
New +$88K 0.01% 652

Other funds holding ECYT

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Verition Fund Management's ECYT Position: Q2 2018 in Review

Verition Fund Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 17,869 shares — an estimated $162K sold.

Verition Fund Management first reported a position in ECYT in Q3 2014 and held it in 2 quarters. The position peaked at $162K in Q1 2018. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

  • Verition Fund Management reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Verition Fund Management sold 17,869 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $162K.
  • Verition Fund Management first reported a position in Endocyte, Inc. Common Stock in Q3 2014 and held it in 2 quarters.
  • Verition Fund Management's Endocyte, Inc. Common Stock position peaked at $162K in Q1 2018.
  • 114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on Verition Fund Management's 13F filing for Q2 2018, filed 15 Aug 2018.